Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NCS-DNA E7 vaccine
- Development stage
- Preclinical
- Lead developer
- Golestan University of Medical Sciences
- Modality
- DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Prophylactic Vaccines → Vaccines & Immunotherapeutics, Nanoparticles → Drug Delivery Systems
- Administration
- Intramuscular
01
Overview
NCS-DNA E7 vaccine is an experimental therapeutic cancer vaccine developed by researchers at Golestan University of Medical Sciences in Iran. The vaccine utilizes a recombinant DNA plasmid encoding the Human Papillomavirus type 16 (HPV-16) E7 oncoprotein, which is a tumor-specific antigen consistently expressed in HPV-associated malignancies. To enhance delivery and immunogenicity, the DNA is encapsulated within a nano-chitosan (NCS) carrier system. Designed for intramuscular administration, the vaccine aims to induce potent E7-specific cellular immune responses, specifically activating CD8+ cytotoxic T lymphocytes and stimulating interferon-gamma production. Preclinical studies in murine models have demonstrated that the NCS-DNA E7 vaccine provides both protective and therapeutic antitumor effects against E7-expressing tumor challenges.
- Other names
- nano-chitosan-DNA E7 vaccinechitosan-DNA E7 vaccineNCS-DNA E7
02
Targets
HPV16 E7 (Human papillomavirus 16 E7 protein)
Beyond the preview
Go deeper on NCS-DNA E7 vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NCS-DNA E7 vaccine.